Albumin for AKI with Ascites in Cirrhosis
Yes, intravenous albumin is indicated for patients with cirrhosis, ascites, and acute kidney injury (AKI), and should be administered at 1 g/kg body weight daily for 2 consecutive days (maximum 100 g/day) after withdrawing diuretics and treating precipitating factors. 1, 2, 3
Initial Management Algorithm for Cirrhotic Patients with AKI and Ascites
Stage 1 AKI (sCr increase ≥0.3 mg/dL within 48h or ≥1.5x baseline)
Immediate actions:
- Withdraw all diuretics, nephrotoxic drugs (NSAIDs, aminoglycosides, contrast), and vasodilators 1, 2
- Treat any identified infections (if spontaneous bacterial peritonitis is present, albumin 1.5 g/kg within 6 hours, then 1 g/kg on day 3) 4, 5
- Expand plasma volume with crystalloids or albumin if hypovolemia is clinically suspected 1, 2
Monitor response over 48 hours - if AKI progresses or fails to resolve, proceed to Stage 2/3 management 1, 2
Stage 2 and 3 AKI (sCr increase ≥2x or ≥3x baseline)
Albumin is the volume expander of choice:
- Administer IV albumin 1 g/kg body weight daily for 2 consecutive days (do not exceed 100 g/day) 1, 2, 3
- This serves dual purposes: treats prerenal AKI and enables differential diagnosis of AKI type 1, 2
- Albumin is superior to crystalloids in cirrhosis because it more effectively restores effective arterial blood volume 3
After 48 hours of albumin therapy, reassess:
- If AKI resolves → continue close monitoring 1, 2
- If no response and meets hepatorenal syndrome-AKI (HRS-AKI) criteria → add vasoconstrictors (terlipressin preferred) plus albumin 20-40 g/day 5, 3
- If structural kidney injury is identified (proteinuria >500 mg/day, microhematuria, abnormal renal ultrasound) → manage as intrinsic AKI with supportive care 1, 2
Critical Evidence Supporting Albumin Use
The 2024 AGA guidelines explicitly state: "IV albumin is the volume expander of choice in hospitalized patients with cirrhosis and ascites presenting with AKI" 5
The International Club of Ascites consensus (2015) established: Lack of response to albumin 1 g/kg for 2 days is a diagnostic criterion for HRS-AKI, making this intervention both therapeutic and diagnostic 1, 2
Recent real-world data (2025) demonstrated: Patients receiving albumin during procedures had 36% lower risk of AKI-related hospitalization (OR 0.64, p=0.03), yet only 41% of eligible patients received guideline-adherent albumin 6
When Vasoconstrictors Are Added
Vasoconstrictors plus albumin are indicated ONLY for:
- Stage 2 or 3 HRS-AKI (not other AKI types) 5, 3
- After failure of initial albumin challenge (1 g/kg × 2 days) 1, 2
- When serum creatinine ≥1.5 mg/dL 1, 2
Vasoconstrictor options (in order of preference):
- Terlipressin 0.5-2.0 mg IV q6h (first-line) 5, 3
- Norepinephrine (alternative, especially if shock present) 3
- Octreotide/midodrine combination (where other agents unavailable) 5
Continue albumin 20-40 g/day with vasoconstrictors, but consider stopping after 1-2 days based on volume status 3
Critical Pitfalls to Avoid
Volume overload monitoring is essential:
- Cirrhotic patients, especially those with cirrhotic cardiomyopathy or diastolic dysfunction, are at risk for pulmonary edema with albumin 5, 3
- Monitor for signs of fluid overload: dyspnea, hypoxemia, pulmonary edema 5
- The FDA label warns that hyperoncotic 25% albumin can expand plasma volume 3-4 times the infused volume 7
Do NOT use albumin for:
- Uncomplicated ascites without AKI 5
- Infections other than spontaneous bacterial peritonitis (increases pulmonary edema risk without benefit) 5
- Chronic hypoproteinemia or nutritional supplementation in cirrhosis 7
Do NOT use furosemide to prevent or treat AKI - diuretics are only indicated for volume overload management (pulmonary edema), not for AKI itself 3
Context: Non-Cirrhotic AKI
For comparison, in non-cirrhotic patients with AKI: